You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Engineered Biotherapeutic Agent for Treatment of Post-Traumatic Osteoarthritis

    SBC: Provizigen LLC            Topic: NIAMS

    PROJECT SUMMARY/ABSTRACT Post-traumatic osteoarthritis (PTOA) is a degenerative disease of cartilage brought on by traumatic injury to the articular joints. Acute joint injury is followed by severe joint pain and inflammation. This results in much more rapid degeneration of cartilage than in other forms of osteoarthritis, due to the joint instability caused by trauma as well as the increase in pro ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes

    SBC: POP Biotechnologies Inc.            Topic: NIA

    Project Summary/Abstract Alzheimer’s disease (AD) currently affects ~6.2 million Americans, and this number is projected to increase to 14 million by 2060 unless novel treatments or interventions to prevent or delay the onset of AD are identified. Harnessing the immune system to prevent or remove Aβ and/or tau pathologies represents a promising disease- modifying therapeutic approach for the tr ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. IND-enabling studies for cell therapy in Parkinson's disease

    SBC: NEONEURON LLC            Topic: 105

    Parkinson’s disease (PD) is a progressive neurodegenerative disease that is currently incurable with significant unmet medical needs. In the US, over a million people suffer from this disease with an estimated cost of $27 billion per year. The mainstay of PD management is symptomatic treatment with drugs that increase dopamine in the striatum. However, the utility of these drugs is significantly ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Noninvasive sleep enhancement and behavior monitoring technologies for Alzheimer's model mice

    SBC: SIGNAL SOLUTIONS LLC            Topic: NIA

    The aims of this project are to develop new technologies to identify and track sleep and wake abnormalities present in mouse models of Alzheimer’s disease (AD), as well as to test a sleep enhancement technology for applications in AD animal research. Signal Solutions, LLC, has previously developed and commercialized a piezoelectric based system for noninvasive, high-throughput sleep and wake mon ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy

    SBC: AFFIRMED PHARMA, LLC            Topic: NEI

    Abstract Radiation induced keratopathy results in significant ocular surface disease, stem cell deficiency, vision loss, discomfort, and subsequent poor quality of life, affecting up to 23% of patients receiving radiation therapy for head and neck malignancies [1]. Studies have pointed out functional roles of corneal neurons and secretory cells of the lacrimal gland in the etiology of radiation in ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Synthetic Antimicrobial Peptoids for Treatment of Chronic Suppurative Otitis Media

    SBC: Maxwell Biosciences, Inc.            Topic: NIDCD

    PROJECT SUMMARY / ABSTRACT The goal of this project is to develop a new, effective treatment for chronic suppurative otitis media (CSOM), a currently uncurable condition involving severe, chronic middle ear infection. CSOM is the most common cause of persistent hearing loss for children in the developing world, and affects 330 million people worldwide. It is characterized by a chronically infected ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Optimization of an HCN1-Selective Inverse Agonist for the Treatment of Peripheral Neuropathic Pain

    SBC: AKELOS INC            Topic: 106

    PROJECT SUMMARY/ABSTRACTIn the United States, at least 116 million adults suffer from chronic pain; the associated costs exceed $500 billion/yr. Neuropathic pain (chronic pain associated with aberrant activity in the central and/or peripheral nervous system) accounts for 18% of patients with chronic pain. Opioid analgesics are routinely prescribed for the treatment of chronic pain but there are su ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Provenance attestation of human cells using physical unclonable functions

    SBC: SyntaxisBio Inc.            Topic: NHGRI

    Project Summary The use of clustered regularly interspaced short palindromic repeats (CRISPR) technologies has spurred myriads of applications critically relevant to human health and, pertinent to the topic of this project, an ecosystem of companies, universities, and governmental laboratories that either offer or are in need of custom CRISPR- based cell line engineering has started to emerge. For ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Assessment of a Microprocessor Ankle for Low Mobility Individuals with Amputation

    SBC: Synchro Motion LLC            Topic: NICHD

    PROJECT SUMMARYMicroprocessor-controlled ankles have been shown to substantially improve mobility and stability in individuals with lower limb amputation, but these devices are typically only available to higher mobility users due to a lack of scientific evidence to justify insurance reimbursement. As such, many of the individuals with lower limb amputation that have the greatest need for advanced ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)

    SBC: BIOSPUTNIK LLC            Topic: NHLBI

    1 ABSTRACT2 Tuberous sclerosis (TS), also called tuberous sclerosis complex, is a rare, multi-systemic genetic and often life-3 threatening disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys,4 heart, eyes, lungs, and skin. Lymphangioleiomyomatosis (LAM) is a TS-related tumor-like disorder. Both occur5 as a consequence of an inherited or sporadic mu ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government